Lebwohl, Mark G.
Blauvelt, Andrew http://orcid.org/0000-0002-2633-985X
Menter, Alan http://orcid.org/0000-0002-9314-0007
Papp, Kim A. http://orcid.org/0000-0001-9557-3642
Guenthner, Scott http://orcid.org/0000-0002-6660-2245
Pillai, Radhakrishnan
Israel, Robert J.
Jacobson, Abby
Funding for this research was provided by:
Amgen
AstraZeneca
Article History
First Online: 14 November 2019
Compliance with Ethical Standards
:
: The brodalumab clinical study program was sponsored by Amgen/AstraZeneca, and this analysis was performed by Amgen/AstraZeneca.
: Mark G. Lebwohl is an employee of Mount Sinai, which receives research funds from AbbVie, Boehringer Ingelheim, Bausch Health, Celgene, Eli Lilly, Incyte, Janssen/Johnson & Johnson, Leo, Medimmune/Astra Zeneca, Novartis, Pfizer, Sciderm, UCB, and Vidac, and is also a consultant for Allergan, Aqua, Arcutis, Boehringer-Ingelheim, Leo, Menlo, and Promius. Andrew Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Aclaris, Akros, Allergan, Almirall, Amgen, Arena, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermavant, Dermira, Eli Lilly, FLX Bio, Galderma, Genentech/Roche, GlaxoSmithKline, Janssen, Leo, Meiji, Merck Sharp & Dohme, Novartis, Pfizer, Purdue Pharma, Regeneron, Revance, Sandoz, Sanofi Genzyme, Sienna Pharmaceuticals, Sun Pharma, UCB, and Vidac and as a paid speaker for AbbVie, Regeneron, and Sanofi Genzyme. Alan Menter has received compensation from or served as an investigator, consultant, advisory board member, or speaker for AbbVie, Allergan, Amgen, Anacor, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, Janssen, Leo, Merck & Co, Neothetics, Novartis, Pfizer, Regeneron, Symbio/Maruho, Vitae, and Xenoport. Kim A. Papp has served as a consultant; scientific officer; member of a speaker’s bureau, advisory board, or steering committee for or received research grants or honoraria from AbbVie, Akesis, Akros, Allergan, Alza, Amgen, Anacor, Artax Biopharma, Astellas, AstraZeneca, Bausch Health, Baxter, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite BioPharma, Celgene, Celtic Pharma, Cipher, Dermira, Dow Pharma, Eli Lilly, Ferring, Formycon, Forward Pharma, Fujisawa, Funxional Therapeutics, Galderma, Genentech, Genexion, Genzyme, Gilead, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin Co, Leo, MedImmune, Meiji Seika Pharma Co, Merck & Co (MSD), Merck Serono, Mitsubishi Tanabe Pharma, Mylan, Novartis, NovImmune, Pan-Genetics, Pfizer, Regeneron, Roche, Sanofi-Aventis, Stiefel Laboratories, Takeda, UCB, and Vertex Pharmaceuticals. Scott Guenthner serves as a speaker for Janssen, Pfizer, AbbVie, Sun Pharma, and Aclaris. Radhakrishnan Pillai is an employee of Bausch Health Americas and may hold stock and/or stock options in the company. Robert J. Israel is an employee of Bausch Health US, LLC and holds stock and/or stock options in the company. Abby Jacobson is an employee of Ortho Dermatologics and holds stocks and/or stock options in Bausch Health US, LLC.
: The study protocol received institutional review board or ethics committee approval at each participating site, and study procedures were conducted in accordance with the ethical principles established by the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study.